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Abstract
Background
Residual Kidney Function (RKF) is associated with survival benefits in haemodialysis (HD)
but is difficult to measure without urine collection. Middle molecules such as Cystatin C and
β2-microglobulin accumulate in renal disease and plasma levels have been used to esti-
mate kidney function early in this condition. We investigated their use to estimate RKF in
patients on HD.
Design
Cystatin C, β2-microglobulin, urea and creatinine levels were studied in patients on incre-
mental high-flux HD or hemodiafiltration(HDF). Over sequential HD sessions, blood was
sampled pre- and post-session 1 and pre-session 2, for estimation of these parameters.
Urine was collected during the whole interdialytic interval, for estimation of residual GFR
(GFRResidual = mean of urea and creatinine clearance). The relationships of plasma Cystatin
C and β2-microglobulin levels to GFRResidual and urea clearance were determined.
Results
Of the 341 patients studied, 64% had urine output>100ml/day, 32.6% were on high-flux HD
and 67.4% on HDF. Parameters most closely correlated with GFRResidual were 1/β2-mico-
globulin (r2 0.67) and 1/Cystatin C (r2 0.50). Both these relationships were weaker at low
GFRResidual. The best regression model for GFRResidual, explaining 67% of the variation,
was:
GFRResidual ¼ 160:3 
1
b2m
 
 4:2
Where β2m is the pre-dialysis β2 microglobulin concentration (mg/L). This model was vali-
dated in a separate cohort of 50 patients using Bland-Altman analysis. Areas under the curve
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in Receiver Operating Characteristic analysis aimed at identifying subjects with urea clearan-
ce2ml/min/1.73m2 was 0.91 for β2-microglobulin and 0.86 for Cystatin C. A plasma β2-
microglobulin cut-off of19.2mg/L allowed identiﬁcation of patients with urea clearance
2ml/min/1.73m2 with 90% speciﬁcity and 65% sensitivity.
Conclusion
Plasma pre-dialysis β2-microglobulin levels can provide estimates of RKF which may have
clinical utility and appear superior to cystatin C. Use of cut-off levels to identify patients with
RKF may provide a simple way to individualise dialysis dose based on RKF.
Introduction
There is increasing evidence that residual kidney function (RKF) is major contributor to long-
term survival in both HD[1, 2] and peritoneal dialysis[3, 4]. Dialysis strategies that protect
RKF may therefore be beneficial. However measuring RKF in HD has not been practiced
widely because of the inconvenience of having to perform urine collections to allow clearance
to be estimated.
It is known that RKF is the major determinant of the plasma levels of many middle mole-
cules even in the dialysis population. On this basis it has been proposed that plasma levels of
middle molecules might be useful as markers of RKF, avoiding the need for urine collection[5,
6]. Cystatin C, β2-microglobulin, and beta trace protein have all been suggested as potential
candidate molecules [5–9].
Cystatin C is a lysosomal protease and cysteine proteinase inhibitor produced by all nucle-
ated cells [10, 11]. At 13.3 kDa, it is of similar size to β2 microglobulin (12.6kDa). Being freely
filtered by glomeruli and metabolised by proximal tubules[12], Cystatin C may be used as an
alternative to creatinine as a marker of glomerular filtration rate (GFR) without the need to
correct for muscle bulk, sex and race both in subjects with normal and moderately impaired
kidney function[13–15]. However, although Hoek et al have reported plasma Cystatin C levels
to be related to RKF in HD patients[6], its value as a plasma predictor of GFR remains unclear
in this setting. Similarly, a close relationship has been found between β2-microglobulin plasma
concentration and RKF in HD [16] and peritoneal dialysis [17, 18]. This relationship also
holds in the context of haemodiafiltration (HDF), a technique that enhances middle molecule
clearance and has now been shown to be improve survival in both retrospective [19, 20] and
prospective randomised control trials in HD[21, 22]. HDF involves the use of high convective
volumes to maximise middle molecule clearance, Even in this setting however, RKF is the
major determinant of plasma levels of β2-microglobulin. Β2-microglobulin is therefore a
potential plasma marker of RKF and at 11.6kDa is of similar size to Cystatin C. Kinetic studies
of generation rate and non-renal clearance suggest that there is lower inter-individual variation
for β2-microglobulin compared to Cystatin C and this suggests a potential closer relationship
between plasma β2-microglobulin levels and RKF than for Cystatin C[23, 24].
In this study we aimed to determine the utility of plasma β2-microglobulin and Cystatin C
concentrations for estimation of RKF in patients on HD. Using regression equations, we aimed
to determine predictive equations for RKF in patients on haemodialysis based on plasma levels
of β2-microglobulin and Cystatin C. We also aimed to determine whether a cut-off middle-
molecule level may be used to identify patients who have significant RKF which might allow
modification of dialysis doses for incremental dialysis[25].
Middle Molecules and Residual Kidney Function
PLOS ONE | DOI:10.1371/journal.pone.0143813 December 2, 2015 2 / 17
funded EV (Fellowship TF9/2010). The funder had no
role in the study design, data collection, analysis,
decision to publish or preparation of the manuscript.
Support was received through the National Institute
for Health Research through the Renal Research
Network. The funder had no role in the study design,
data collection, analysis, decision to publish or
preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Methods
Study design and setting
The study was performed with approval from the Hertfordshire (UK) Research Ethics Com-
mittee (Reference 09/H0311/07) and in accordance with the Declaration of Helsinki. The ethics
committee reviewed the consent process and agreed that verbal but not written consent would
be required from subjects as no additional blood draws would be required due to sampling of
blood being simultaneous with routine monthly samples and three other markers of renal func-
tion already being tested routinely (urea, creatinine, β2-microglobulin) with the only additional
marker being cystatin C. For inclusion patients were required to be>18 years and on regular
dialysis at the East and North Herts NHS Trust. There were no exclusion criteria. Patients were
provided with an information sheet>24hours prior to study participation and their verbal
consent was documented in both hospital medical notes and study records.
341 patients established on chronic thrice weekly high-flux HD or on-line HDF were
recruited as a test cohort. All subjects had a measure of RKF and sampling of plasma pre and
post-dialysis urea, creatinine, cystatin C and β2 microglobulin to determine predictive models
for estimating RKF from plasma levels. Refusal to participate was not formally recorded but
was very low (<10%) as the study was performed simultaneously with routine monthly dialysis
blood samples and urine collections for RKF were routinely performed in the dialysis unit in all
uric patients.
Predictive models from this test cohort were validated in an entirely separate cohort
(n = 50) of patients from the same centre. This sample was recruited at a different time point
while ensuring zero cross-over between patients in the two groups.
Haemodialysis and on-line haemodiafiltration procedures
All patients were dialysed using Fresenius 5000 series or Nikisso HD machines using high-flux
HD or online HDF. Where HDF was used it was used as a permanent treatment modality and
switching between high-flux HD and HDF on a session-by-session basis (eg. once a week
HDF) was nor performed. Data recorded included blood flow (QB), dialysis fluid flow (QD),
ultrafiltration volume(UF) and body size parameters on the first dialysis session of the week.
Body Surface Area (Dubois formula) was calculated from the weight and height. Bicarbonate
was used as a buffer, and ultrapure water used both for dialysis and replacement fluid for online
HDF. 94% of patients used Fresenius FX-class high-flux dialysers. All dialysed using an incre-
mental algorithm whereby target total Kt/V (Kt/VTotal) at 1.2 was the sum of dialysis two-pool
eKt/V (Kt/VDialysis) and the equivalent Kt/V provided by RKF (Kt/VRenal) [1, 26, 27]. For online
HDF, the HDF fraction was 0.35 of plasma flow rate and target HDF volume/session was 40%
of Watson volume.
Measurement of residual kidney function
Residual GFR (GFRResidual) was measured using the mean of urea and creatinine clearance cal-
culated from interdialytic urine collection and then corrected to 1.73m2. Patients with
<100ml/day urine output were regarded as having zero GFRResidual. Urea and creatinine clear-
ance were calculated using the formula:
Clearanceðml=minÞ ¼ 2  ðUID  VIDÞ
tID  ðCpostHD1 þ CpreHD2Þ
Where UID is the urinary concentration, VID is the urine collection volume (ml), tID is the
Middle Molecules and Residual Kidney Function
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collection duration (min), and Cpost_HD1 and Cpre_HD2 are the plasma concentrations at the
beginning and end of the urine collection.
Sampling of blood for clearance markers
Over consecutive dialysis sessions (HD1 and HD2), blood samples were drawn pre- and post-
HD1 and pre-HD2. HD1 was the dialysis session immediately following the weekend. Pre dial-
ysis samples were drawn from the arterial needle immediately before dialysis. Post-dialysis
samples were taken at the end of treatment with the blood pump slowed to 50ml/min for 30
seconds prior to sampling to reduce access recirculation. Samples were analysed for urea, creat-
inine, β2-microglobulin and Cystatin C. β2-microglobulin was measured using an Olympus
AU640 (Beckman-Coulter) by immune-turbidimetric analysis. Cystatin C was measured on an
IMMAGE1800 (Beckman-Coulter) analyser using DakoCytomation Cystatin C reagent (Dako
Ltd, Cambridgeshire, UK) based on the non-competitive rate particle-enhanced nephelometric
technology. Repeat analysis of patient samples showed< 3% inter-assay variation for both
Cystatin C and β2-microglobulin.
Dialysis Reduction Ratios
For each molecule, the reduction ratio during dialysis was calculated for HD1 as:
½ðCpre HD1Cpost HD1Þ=Cpre HD1 100%:
Dialysis single pool Kt/Vurea was calculated using the Daugirdas 2
nd generation formula[28]
and the equilibrated Kt/Vurea using the Tattersall transformation[29].
Statistical methods
Demographic parameters in the test and validation cohorts were compared using T-tests,
Mann-Whitney U tests and Fisher’s Exact test as appropriate.
Pre-HD levels of β2-microglobulin and Cystatin C, their reciprocals and their inter-dialytic
rise were related to estimates of RKF (GFRResidual, urea and creatinine clearance) using Pear-
son’s correlation.
Predictive equations for RKF were determined based on pre-HD plasma concentrations of
the above molecules using linear regression including (Eq 1, Results).
Receiver Operating Characteristic (ROC) analysis was used to determine cut-off plasma
urea, creatinine, Cystatin C and β2-microglobulin concentrations which identified patients
having varying degrees of RKF. Various levels of RKF were studied using urea clearance and
GFRResidual between 1 and 10ml/min/1.73m
2 BSA. For each RKF cut-off level the plasma con-
centrations of Cystatin C and β2-microglobulin were determined that would yield a false posi-
tive rate of<10% (specificity 90%).Similar ROC analyses were performed to identify patients
with GFRResidual various levels using predicted GFR from the optimum regression equation
(Eq 2, Results) as the test variable.
To determine the relationships of plasma Cystatin C and β2-microglobulin levels with over-
all urea-based adequacy measures, the correlations of Kt/VTotal with pre-dialysis plasma levels,
and their reciprocals, were assessed.
Validation of methods to predict RKF in a separate cohort
Demographics of the study cohort were compared to the validation cohort using parametric/
non parametric tests as appropriate. The best derived predictive equation for GFRResidual based
on a single plasma middle molecule concentration was applied to the validation cohort
Middle Molecules and Residual Kidney Function
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(n = 50) and its performance assessed using the Bland-Altman technique. Additionally, the
cut-off plasma concentration level of middle molecules that had been determined to identify
patients with significant RKF were applied to the validation cohort to determine the sensitivity
and specificity of the tests.
Results
Study population
341 subjects were recruited, of whom 111 were treated with high-flux HD and 230 using online
HDF (Table 1). 36% of patients had RKF classified as zero. Demographic, clinical and dialysis
characteristics in the test cohort are shown in Table 1. 35.1% of patients had residual kidney
function of zero. Mean total Kt/V (eKt/Vurea+ Kt/VRenal) was 1.33 ± SD 0.22 and mean dialysis
eKt/Vurea was 1.14 ±SD 0.26 which reflects the incremental HD algorithm.
In the validation cohort, demographic parameters did not differ significantly from the test
cohort and are reported in Table 2. 34% of the validation cohort had RKF classified as zero.
Mean plasma concentrations are shown in Table 3. Pre-HD1 concentrations (Monday or Tues-
day) were significantly higher than pre-HD2 (Wednesday or Thursday) with p<0.001 for each
pair molecule (paired t tests).
Dialysis clearance of Cystatin C and β2-microglobulin
Reduction ratios for all molecules are shown in Table 2. Cystatin C reduction ratio correlated
highly with β2-microglobulin reduction ratio (r2 = 0.70,p<0.001). In linear regression analysis
controlling for eKt/Vurea, treatment modality (high-flux HD v HDF) was an independent pre-
dictor of Cystatin C reduction ratio, HDF being associated with a 7% increase compared to
high-flux HD (p< 0.001). Similarly HDF was associated with an 8% increase in β2-microglo-
bulin reduction ratio (p<0.001).
Table 1. Baseline characteristics and dialysis parameters of the study population.
Descriptive Mean, Median †, or percentage Standard deviation, IQR*
Demographics Age 62.7 17
Males/Females (%) 65.7% M, 34.4% F
Weight (kg) 75.7 18.8
Watson Volume (L) 38.7 8.1
Body surface area (m2) 1.85 0.27
Dialysis parameters Dialysis time (min) 190 32
Blood ﬂow [Qb] (ml/min) 329 65
Dialysis ﬂuid ﬂow [Qd] (ml/min) 690 146
High-ﬂux HD/HDF (%) 32.6% High-ﬂux HD, 67.4% HDF
Ultraﬁltration (L) 1.66 1.02
GFR (ml/min/1.73m2 BSA) 1.13† 4.44*
Dialysis single pool Kt/Vurea 1.35 0.29
Dialysis eKt/Vurea 1.14 0.26
Residual renal equivalent Kt/V 0.10† 0.30*
Total Kt/Vurea (Renal+Dialyser) 1.33 0.22
Total Kt/Vurea represents the sum of residual renal and dialyser clearance which was used for incremental dialysis calculations and as target Kt/V (see
methods).
† Median.
* Interquartile range.
doi:10.1371/journal.pone.0143813.t001
Middle Molecules and Residual Kidney Function
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Pre-dialysis concentration of β2 microglobulin was similar between the high-flux HD and HDF
groups overall (mean 27.1±SD9.6mg/L v 26.3±SD7.8, p = 0.4) but in those with low level RKF
(GFR<1ml/min/1.73m2 BSA) it was significantly lower (35.5±SDmg/L v 31.1±SD5.9, p<0.001).
Relationship of residual kidney function to plasma Cystatin C and β2
microglobulin levels
The parameter correlating best with GFRResidual, urea clearance and creatinine clearance was
the reciprocal of pre-dialysis HD1 β2-microglobulin (r2 0.67, 0.57, 0.68 respectively, Table 4).
The reciprocal of pre-dialysis HD1 Cystatin C level correlated to a lesser degree (r2 0.50, 0.44
and 0.48 for respectively). These relationships are shown in Figs 1 and 2. The correlations
between the interdialytic rise (post HD1 to pre HD2) in both plasma β2 microglobulin and
Cystatin C levels and GFRResidual, urea and creatinine clearances, were weaker (Table 4).
Linear regression equations for GFRResidual corrected to 1.73m
2 based on the reciprocal of
pre-dialysis β2 microglobulin and Cystatin C levels were computed as follows:
GFRResidual ¼ slope 
1
PreHD1 level
 
þ constant ðEquation 1Þ
where for β2 microglobulin (mg/L) slope = 160.3 (CI 147.5–173.1) and constant = -4.2 (CI -4.8
Table 2. Demographics of the validation cohort.
Descriptive Mean, Median †, or percentage Standard deviation, IQR* Comparison to test cohort (p)
Demographics Age 59.6 17.2 0.22
Males/Females (%) 30% M, 70% F 0.63
Weight (kg) 79.7 20.4 0.43
Watson Volume (L) 40.2 8.6 0.21
Body surface area (m2) 1.90 0.26 0.24
Dialysis parameters Dialysis time (min) 210 29 0.03
Blood ﬂow [Qb] (ml/min) 329 65 0.53
High-ﬂux HD/HDF (%) 18% High-ﬂux HD, 82% HDF 0.05
Ultraﬁltration (L) 1.7 1.00 0.99
GFR (ml/min/1.73m2 BSA) 1.94† 4.38* 0.81
Dialysis eKt/Vurea 1.10 0.28 0.08
Residual renal equivalent Kt/V 0.23† 0.43* 0.14
Total Kt/Vurea (Renal+Dialyser) 1.35 0.30 0.76
† Median
* Interquartile range (IQR)
doi:10.1371/journal.pone.0143813.t002
Table 3. Plasma levels of molecules at each study time-point
Plasma levels (mean±SD) Paired T test comparison of Pre-HD1 v Pre-HD2
(p)
Reduction ratio over
HD1
Pre-HD1 Post-HD1 Pre-HD2
Urea (mmol/L) 22.7 ± SD6 7.1 ± SD2.7 19.2 ± SD5.1 <0.001 69%± SD7%
Creatinine (μmol/L) 827 ± SD256 296 ± SD103 734 ± SD233 <0.001 63%± SD8%
β2-microglobulin
(mg/L)
26.6 ± SD8.4 9.2 ± SD3.4 24.6 ± SD7.4 <0.001 64%± SD10%
Cystatin C(mg/L) 5.3 ± SD1.1 2.6 ± SD0.6 5.2 ± SD1 <0.001 51%± SD11%
SD Standard Deviation
doi:10.1371/journal.pone.0143813.t003
Middle Molecules and Residual Kidney Function
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to -3.6), r2 = 0.67. For Cystatin C (mg/L) slope = 56.4 (CI 49.9–62.9) and constant = -8.4 (CI
-9.6–-7.1), r2 = 0.50.
The above model for GFRResidual corrected to 1.73m
2 BSA could be improved marginally
(r2 0.68) by inclusion of both reciprocal pre-dialysis β2 microglobulin levels and pre-dialysis
weight:
GFRResidual ¼ A 
1
PreHD1 b2m
 
þ B  1
PreHD1 creatinine
 
þ C Weight þ constant ðEquation 2Þ
where units are β2-microgloculin (mg/L), creatinine(μmol/L), weight(kg). In this model regression
parameters were A = 142.2(CI 125.6 to 158.9), B = 899.8 (CI 309.3 to 1490.4), C = 0.013 (CI 0.002 to
0.024), constant = -5.63 (CI-6.70 to -4.55). Addition of other demographic variables such as age did not
improve the model further.
Regression parameters were very similar if patients who were anuric were excluded. For
instance, for Eq 1 based on reciprocal β2-microglobulin level the model r2 was 0.61 where we
excluded these patients compared to 0.67 otherwise.
Use of cut-off plasma levels of Cystatin C and β2-microglobulin to
identify patients with significant residual kidney function
ROC curves for pre-dialysis plasma Cystatin C, β2-microglobulin, urea and creatinine as indi-
cators of residual kidney urea clearance2ml/min/1.73m2 BSA are shown in Fig 3. Areas
under each curve were 0.91 (CI 0.87–0.94) for β2-microglobulin, 0.86 (CI 0.82–0.90) for Cysta-
tin C, 0.74 (CI 0.68–0.80) for creatinine and 0.43 (CI 0.35–0.50) for urea.
Using ROC analyses, for various levels of RKF considered significant (urea clearance
1-5ml/min and GFR 1-10ml/min/1.73m2 urea clearance), the cut-off level of β2-microglobulin
was determined below which patients with each level of RKF could be identified with>90%
specificity (false positive rates of<10%). Table 5 and Table 6 show for each relevant cut-off
level the sensitivity and Area Under the Curve of the ROC analysis. It can be seen that identify-
ing patients with urea clearance4 ml/min/1.73m2 BSA using a β2 microglobulin level cut-off
Table 4. Correlation of pre-dialysis Cystatin C and β2 microglobulin plasma levels and their interdialytic rise with variousmeasures of RKF
Cystatin C β2
microglobulin
1/Cystatin C 1/ β2
microglobulin
Interdialytic rise
in Cystatin C
Interdialytic rise in
β2 microglobulin
Pearson
Correlation
-0.66 -0.72 0.71 0.82 -0.56 -0.69
GFRResidual
(ml/min/1.73m2)
r2 0.433 0.517 0.503 0.672 0.311 0.482
Sig. (p) <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Pearson
Correlation
-0.62 -0.69 0.66 0.76 -0.53 -0.67
Urea clearance
(ml/min/1.73m2)
r2 0.39 0.47 0.44 0.57 0.28 0.44
Sig. (p) <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Pearson
Correlation
-0.62 -0.68 0.69 0.82 -0.53 -0.66
Creatinine clearance
(ml/min/1.73m2)
r2 0.39 0.46 0.48 0.68 0.28 0.44
Sig. (p) <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
GFRResidual = the measured residual GFR (mean of urea and creatinine clearances).r
2 is the square of the Pearson correlation coefﬁcient.
doi:10.1371/journal.pone.0143813.t004
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of16.3 mg/L had 100% sensitivity and 90% specificity (Table 5). Likewise a cut-off of
16.7mg/L identified patients with a GFR 10 ml/min/1.73m2 BSA with similar levels of sen-
sitivity and specificity (Table 6). However, for both clearances, identifying patients with lower
levels of RKF had much lower sensitivity.
Validation of methods to estimate RKF in the validation cohort
Mean age of the validation cohort was 59.6 years±SD17.2 and proportion of males 70% which
did not differ significantly from the study cohort (p = 0.24 and p = 0.63).
The predictive model for GFR based on β2 microglobulin plasma level was applied to the
validation cohort. The Pearson’s correlation r2 between predicted and measured GFR was 0.55.
Fig 1. Relationship of GFR with the reciprocal of pre-dialysis β2microglobulin levels.GFR shown is calculated frommean of urea and creatinine
clearance. For the linear regression shown r2 was 0.67.
doi:10.1371/journal.pone.0143813.g001
Middle Molecules and Residual Kidney Function
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Using Bland-Altman analysis, the bias was 1.40 ml/min(±SD1.92) and 95% limits of agreement
-2.35 to 5.16ml/min (Fig 4).
Use of the cutoff β2 microglobulin level of19.15mg/ml (Table 5) to identify patients with
urea clearance>2ml/min/1.73m2 BSA was tested in the validation cohort. Sensitivity was
54.2% and specificity 92.3%, similar to that predicted (Table 5). Positive predictive value was
86.7% and negative predictive value 68.6%.
Discussion
In this study we have compared the potential use of two middle molecules to predict RKF.
β2-microglobulin appears to be more closely correlated than Cystatin C with RKF. However,
although reciprocal β2 microglobulin and Cystatin C in linear regression explain 67% and 50%
Fig 2. Relationship of GFR with the reciprocal of pre-dialysis plasma Cystatin C levels.GFR shown is calculated from the mean of urea and creatinine
clearance. For the linear regression shown r2 was 0.5.
doi:10.1371/journal.pone.0143813.g002
Middle Molecules and Residual Kidney Function
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Fig 3. ROC analysis of pre-dialysis levels of Cystatin C, β2-microglobulin, urea and Cystatin C to identify patients with significant residual renal
urea clearance2ml/min/1.73m2 BSA. The greatest area under the curve was for β2-microglobulin.
doi:10.1371/journal.pone.0143813.g003
Middle Molecules and Residual Kidney Function
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of the variation in GFR respectively, their predictive value as plasma measures of RKF may be
limited. This is because at lower levels of GFR, particularly<5ml/min, the relationship between
their plasma levels and GFRResidual is weaker. Inclusion of other parameters in the regression
model (reciprocal creatinine concentration, weight) only marginally improved the regression
model for GFRResidual.
Previously, Hoek et al determined a predictive equation for GFR in dialysis patients based
on Cystatin C plasma concentration[6] but our data suggests that use of β2-microglobulin, or
its reciprocal, holds more promise. We describe an algorithm to estimate GFR based on pre-
HD β2-microglobulin: a simple regression using plasma concentration only. However, substan-
tial variance remains unexplained and the performance of this equation in our validation
cohort (r2 only 0.55) suggests that pre-dialysis plasma β2 microglobulin levels do not explain
sufficient variance in GFR to provide an adequate clinical predictor on an individual patient
basis. However, this equation may be useful as a research tool where an estimate of kidney
function is required in a large cohort, for instance in survival analyses where correction for
level of RKF is desired due to its large impact on outcomes.
However, the use of a cut-off pre-dialysis plasma level to identify patients with significant
RKF shows more promise. KDOQI guidelines suggest permitting a reduction in minimum
standard Kt/V for HD if urea clearance2ml/min/1.73m2 BSA, and ignoring RKF below this
Table 5. Β2-microglobulin level cut-off levels that may be used to identify patients with residual renal urea clearance. For various levels of residual
urea clearance, the cut-off β2-microglobulin level was determined that would yield a false positive rate (specificity) of 10%. For each level of urea clearance
area under the curve (AUC) is shown for ROC analyses.
RKF level (ml/min/1.73m2
urea clearance)
Number of patients with RKF  level
in column 1 in cohort
Cut-off β2m microglobulin level
(mg/L) for positive test
Sensitivity Speciﬁcity AUC
1 139 23.30 0.72 0.90 0.92
2 79 19.15 0.65 0.90 0.91
3 46 18.40 0.73 0.90 0.94
4 19 16.70 0.63 0.90 0.91
5 7 16.30 1.00 0.90 0.96
AUC: Area under the curve
doi:10.1371/journal.pone.0143813.t005
Table 6. B2-microglobulin level cut-off levels that may be used to identify patients with residual renal function measured as GFR. For various levels
of GFR the cut-off β2 microglobulin level was determined that would yield a false positive rate (specificity) of 10%. For each GFR level area under the curve is
shown for ROC analyses.
(GFR in ml/min/
1.73m2 BSA)
Number of patients with RKF  level in
column 1 in cohort
Cut-off β2m microglobulin level (mg/L)
for positive test
Sensitivity Speciﬁcity AUC
1 155 24.05 0.7 0.90 0.89
2 130 23.65 0.76 0.90 0.92
3 104 21.80 0.77 0.90 0.91
4 84 20.40 0.75 0.90 0.92
5 64 19.05 0.67 0.90 0.91
6 48 18.85 0.71 0.90 0.93
7 29 18.05 0.83 0.90 0.95
8 18 17.45 0.94 0.90 0.96
9 16 17.35 0.94 0.90 0.97
10 11 16.70 1.00 0.90 0.98
AUC: Area Under the Curve
doi:10.1371/journal.pone.0143813.t006
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level[25]. However, a lower level of1ml/min/1.73m2 BSA has previously been associated
with survival benefit [1]. Fig 3 demonstrates that pre-dialysis β2-microglobulin is most useful
for identifying patients with significant RKF. A cut-off of<19.15mg/L is required to identify
patients with2ml/min/1.73m2 urea clearance while ensuring a low false positive rate of
<10%, and we demonstrated its use in a validation cohort. This may allow for a reduction in
minimum standard Kt/V target in selected individuals without the requirement for urine col-
lection, though the sensitivity of this cut-off is low (65%).
It may be surprising that the interdialytic rise in Cystatin C was not more closely related to
RKF, given that Cystatin C levels are less affected by muscle mass than creatinine and one
might expect the magnitude of inter-dialytic rise to be predominantly defined by RKF. How-
ever at low GFR the non-renal Cystatin C clearance, estimated at 22.3ml/min/1.73m2 domi-
nates over renal clearance in advanced kidney failure and is subject to wide inter-individual
variation [24, 30]. it is not surprising therefore that a single pre-dialysis plasma concentration
of this molecule is not the optimum marker for estimating GFR.
Use of reciprocal of β2-microglobulin or Cystatin C plasma levels in regression equations to
predict RRF may be useful as research tools such as in prospective studies of survival in HD
where correction for level of RRF is important. Serial plasma measurement of these molecules
could, in survival analyses, allow for correction of RRF and take into account its time-depen-
dent variation without the need to perform repeated urine collections for clearance.
A further potential use of β2-microglobulin or Cystatin C may be as markers of improving
kidney function in subjects with acute kidney injury requiring dialysis. A plasma β2 microglo-
bulin level of16.7mg/L identified among the dialysis population those with GFR10ml/min/
1.73m2 BSA with a low 10% false positive rate (Table 5). This potentially clinically useful cut-
off level should be further explored and validated in the context of acute kidney injury. How-
ever, the numbers of patients with GFR10ml/min was low in the sample and we advise con-
siderable caution with the sensitivities and specificity reported at this GFR cutoff.
In our study, we included all established patients on dialysis and did not exclude those who
were anuric, or who had low level urine volume. In our view it was essential to include such
patients to understand the limitations of using middle molecules to predict very low level RKF.
Fig 4. Bland-Altman analysis showing performance of Eq 1 for predicting GFR (ml/min/1.73m2 BSA) based on pre-dialysis β2-microglobulin
plasma concentration.
doi:10.1371/journal.pone.0143813.g004
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Even low level RKF (urea clearance>1ml/min/1.73m2 BSA) appears to confer a large survival
benefit and it is likely to be useful to identify such individuals[1]. Excluding such patients
would have limited the applicability of our models in such patients with low level kidney
function.
In this study all patients were treated with either HDF or high-flux HD. Convective volumes
are much greater in HDF though in high-flux HD a degree of internal convection occurs[31].
We demonstrated that β2 microglobulin levels were lower in patients treated with HDF com-
pared to high-flux HD in the subgroup whose GFR was<1ml/min/1.73m2 BSA which demon-
strated again the dominant effect of RKF in defining plasma levels and perhaps explains why in
the ESHOL study where a large proportion of patients would have had RKF no substantial dif-
ference in β2 microglobulin levels was found between high-flux HD and HDF groups[21]. Nev-
ertheless, the substantial effect of HDF in increasing β2-microglublin clearance suggests that
cut-off levels for this molecule used to identify significant GFR might differ in the high-flux
HD and HDF populations, and this is confirmed by the contribution of total convective volume
to the prediction of GFR in Eq 2. However addition of HDF to Eq 1 did not improve its predic-
tive value.
This study has a number of limitations. The large number of patients precluded measure-
ment of GFR with a “gold-standard”measure such as 51-Cr-EDTA. Although measuring GFR
from interdialytic urine collections has limitations, these were reliably performed in our unit
where, as part of our incremental HD programme, patients are well-accustomed to performing
monthly urine collections. There is a paucity of data available on week-to-week GFR variation
on HD, but this study did not investigate this aspect, instead aiming to determine whether a
single plasma sample predicts GFR at a specific time point. Our study had did not have an
external validation cohort and our regression algorithms require validation in other dialysis
populations. Our regression models for RKF based on pre-dialysis β2 microglobulin concentra-
tions were derived in our population dialysing with high-flux membranes and models are not
generalizable to patients using low-flux membranes in whom plasma concentrations may be
higher. However, as RKF is the dominant predictor of plasma β2 microglobulin concentration
we suggest that even in the low flux setting it may be a useful (or even better!) marker of RKF.
An additional limitation, specific to Cystatin C, is that this molecule forms dimers as part of
the normal cellular processing pathway [32]. The degree to which these are measured by Cysta-
tin C assays including the one employed in this study is unknown. This is important since
Cystatin C dimerisation and binding to proteins such as C4 complement[33] may reduce the
effective Cystatin C available for removal during dialysis, and is likely to enhance the post-dial-
ysis rebound for this molecule. The methodology used to measure Cystatin C in our study was
particle-enhanced DAKO immunoturbidimetric immunoassay whereas other techniques
employed have included the immunonephelometric immunoassay[6]. Although these correlate
highly (r = 0.97) bias exists[34] so the predictive models for GFR described by us may be spe-
cific to our measurement technique. The DAKOmethod has the advantage that the analytical
coefficient of variation is lowest in the pre-dialysis cystatin C range observed in patients on HD
[34].
With regard to β2-microglobulin, there are limitations to its use as a predictor of RKF
which should be taken into account. CRP has been shown to related to its plasma level in multi-
variate analysis[16], is elevated in certain inflammatory conditions including HIV infection
[35] and also in haematological conditions including myeloma[36]. It is subject to significant
variation in non-renal clearance and is sequestered in body compartments which make its
kinetics complex[37].Nonetheless, although its exhibits large post-dialysis rebound in both
high flux HD and HDF, like Cystatin C it does appear to reach plateau in the inter-dialytic
period so its levels reach equilibrium[24] and at this point plasma concentration is likely to
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reflect the balance of production and clearance. The relatively large inter-individual variation
in plasma concentration in patients whose RKF is zero seen with both β2 microglobulin(Fig 1)
and cystatin C is likely to therefore represent individual variation in generation rate and non-
renal clearance which limits their use as a markers of RKF at the very low range GFR. However,
changes over time in plasma concentrations of β2 microglobulin may more closely reflect RKF
in individual patients and this requires further exploration.
Although the purpose of our study was to explore use of middle molecules to predict RRF in
the dialysis population, a further proposed use might be as markers of dialysis clearance[38].
Accumulation of β2-microglobulin is harmful in end-stage renal failure with dialysis-related
amyloid [39, 40]. Whether Cystatin C accumulation is harmful is currently a topic of interest,
with recent data showing an association between Cystatin C level and cardiovascular mortality
[41].The extent to which plasma concentration of these markers is affected by inflammation is
unclear, but it is known that β2-microglobulin concentration is related to CRP levels[16].
In conclusion, although there has been considerable interest on use of Cystatin C for pre-
dicting GFR, our study suggests that in the dialysis setting β2-microglobulin plasma concentra-
tion is a superior marker. The limitations of using Cystatin C for predicting GFR in advanced
CKD and the dialysis population relate to unpredictable non-renal clearance[24]. Although we
report regression models for GFR based on pre-dialysis concentrations of these middle mole-
cules, we advise significant caution if these are used on an individual patient basis particularly
due to accuracy at low levels of RKF. However, cut-off levels of β2-microglobulin pre-dialysis
plasma concentration may be more useful clinically to identify those with significant kidney
function (urea clearance2ml/min/1.73m2 BSA) for the purpose of incremental haemodialysis,
recognising that sensitivity of this test is limited. For identifying a higher level of kidney func-
tion (GFR10ml/min.1.73m2 BSA), that might indicate potential independence from dialysis,
sensitivity and specificity are higher and use of pre-dialysis β2-microglobulin concentration for
this purpose should be further explored.
Supporting Information
S1 Dataset. Raw data file. Raw data is shown for the modelling and validation cohort in Excel
format.
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